Navigation Links
NanoBio Awarded U.S. Patent for RSV Vaccine
Date:12/19/2016

ANN ARBOR, Mich., Dec. 19, 2016 /PRNewswire/ -- NanoBio Corporation today announced the issuance of U.S. Patent No. 9,492,525 Human Respiratory Syncytial Virus (RSV) Vaccine. The patent broadly covers the composition of NanoBio's intramuscular and intranasal RSV vaccine candidates, which combine the company's innovative nanoemulsion (NE) adjuvant with strain L19 of RSV. Additional patent applications covering the combination of the NE adjuvant with other strains of RSV and with RSV F protein are currently being pursued.

"This critical patent strengthens NanoBio's position as we prepare to advance our NE RSV vaccine into clinical studies," said Dr. Ali Fattom, Senior Vice President of Vaccine Research and Development, NanoBio. "Based on our research to date, the use of whole inactivated RSV L19 in combination with our NE adjuvant elicits robust protection across multiple strains of RSV in both cotton rats and non-human primates, without evidence of safety concerns or the enhancement of disease observed with prior formalin-inactivated vaccines."

Formulation of RSV L19 virus with NanoBio's NE adjuvant splits and fully inactivates the virus as a result of the adjuvant's inherent antimicrobial properties, yet the immunogenicity of L19's native viral proteins is preserved. The resulting NE RSV vaccine incorporates all of the viral epitopes-including F, G and other proteins-enabling a potentially much broader immune response than what is elicited by subunit vaccine candidates.

About RSV

Respiratory syncytial virus, commonly referred to as RSV, is a highly contagious viral disease and is one of the most common causes of bronchiolitis and pneumonia. Up to 2.5 million infections occur in the U.S. each year. It is the number one cause of childhood hospitalization globally. Nearly all children are infected with the virus at least once by the age of two to three years, and many develop pulmonary disease and/or asthma that persists throughout adult life, making them susceptible to re-infection. The disease is particularly dangerous for premature babies, children with preexisting health conditions and the elderly. RSV is responsible for 16,000 deaths each year in adults older than 65. Currently, there are no approved vaccines for RSV.

About NanoBio

Headquartered in Ann Arbor, Michigan, NanoBio® Corporation is a privately-held biopharmaceutical company focused on developing and commercializing vaccines and anti-infective treatments derived from its patented NanoStat® technology platform. The company's NanoStat® vaccine technology employs a novel oil-in-water nanoemulsion (NE) that can incorporate, deliver and adjuvant multiple antigen types. The NE adjuvant is effective when administered via intranasal or intramuscular vaccination. When applied intranasally, NE vaccines elicit both mucosal and systemic immunity.

NanoBio is currently developing NE vaccines for several respiratory and sexually transmitted diseases, including RSV, pertussis, pandemic influenza, anthrax, and prophylactic and therapeutic HSV2.

For more information on NanoBio or its products, please visit www.nanobio.com.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nanobio-awarded-us-patent-for-rsv-vaccine-300381040.html


'/>"/>
SOURCE NanoBio Corporation
Copyright©2016 PR Newswire.
All rights reserved


Related biology technology :

1. Global Nanobiotechnology Report 2015-2025 - Focus on Applications, Markets and Companies with Profiles of 250+ Companies - Research and Markets
2. Global Nanobiotechnology Report 2016 - Applications, Markets and Companies Analysis to 2025 -- Research and Markets
3. Global Nanobiotechnology Report 2016-2025 - Profiles of 248 Companies with their 180 Collaborations
4. Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024
5. Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies
6. Global Nanobiotechnology Report 2015 - Applications, Markets and Companies Forecasts to 2024
7. NanoBio To Present Data At ICAAC Supporting The Development Of Safe And Effective RSV & Herpes Simplex Virus-2 Vaccines
8. SRI Awarded $150 Million NIAID-DAIDS Contract to Provide Development and Manufacturing Support for Promising HIV-Prevention Products
9. Salk Institute awarded $25 million grant from Helmsley Charitable Trust
10. Lajollacooks4u Awarded TripAdvisor’s 2016 Certificate of Excellence
11. Worcester Polytechnic Institute Team Awarded Patent for Reprogramming Skin Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... Producers of the award ... Inc. in an upcoming episode, scheduled to broadcast fourth quarter 2017. American Farmer ... Hybrids, the independent, family-owned seed company. Educating audiences about its broad portfolio of ...
(Date:8/16/2017)... King of Prussia, PA (PRWEB) , ... August 16, 2017 , ... ... leaders will be taking part in sessions at the ISPE Annual Meeting and ... the Marriott Marquis San Diego Marina. The event’s theme is “Driving innovation to advance ...
(Date:8/16/2017)... Columbus, OH (PRWEB) , ... August 16, 2017 ... ... of a beneficial microbe delivery system, announced it has secured $2M in funding ... Funds, Queen City Angels, Carmen Innovations, and SVG Thrive Fund. With this investment, ...
(Date:8/15/2017)... After spending the past two years building a state-of-the-art ... GeneFo now offers this platform to healthcare stakeholders (hospitals, foundations, biopharma ... and data collection vis a vis their members, under their own ... of this offer. ... ...
Breaking Biology Technology:
(Date:7/20/2017)... (NYSE: DAL ) customers now can use fingerprints instead of ... Airport (DCA). ... Delta launches biometrics to board aircraft at Reagan Washington National Airport ... Delta,s biometric boarding pass experience that launched in May ... boarding process to allow eligible Delta SkyMiles Members who are enrolled in ...
(Date:5/16/2017)... 2017  Veratad Technologies, LLC ( www.veratad.com ), an ... identity verification solutions, announced today they will participate as ... 15 thru May 17, 2017, in Washington ... Center. Identity impacts the lives of ... quickly evolving digital world, defining identity is critical to ...
(Date:4/18/2017)... Inc., a global expert in SoC-based imaging and computing solutions, has ... features the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® ... be showcased during the upcoming Medtec Japan at Tokyo Big Sight ... Las Vegas Convention Center April 24-27. ... Click here for an image of the ...
Breaking Biology News(10 mins):